Metoclopramide and Bupropion: Significant Drug Interaction Risk
The combination of metoclopramide and bupropion should be avoided or used with extreme caution due to a clinically significant pharmacokinetic interaction that increases the risk of seizures and neuropsychiatric adverse events.
Mechanism of Interaction
Bupropion is a potent CYP2D6 inhibitor, along with its active metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion) 1, 2. While metoclopramide is not primarily metabolized by CYP2D6, the interaction concern stems from two critical safety issues:
1. Seizure Risk Amplification
- Bupropion lowers the seizure threshold and is contraindicated in patients with seizure disorders 3, 4, 3
- The seizure risk with bupropion monotherapy is approximately 0.1% (1:1000 patients) 3
- Metoclopramide is a dopamine antagonist that can independently affect neurological function 5
- Combining drugs that lower seizure threshold with bupropion requires extreme caution 1
The FDA drug label explicitly warns: "Use extreme caution when coadministering bupropion hydrochloride extended-release tablets (XL) with other drugs that lower the seizure threshold" 1. While metoclopramide is not specifically listed, its dopaminergic effects and CNS activity warrant consideration.
2. Neuropsychiatric Effects
Both medications carry neuropsychiatric warnings:
- Bupropion: Black box warning for neuropsychiatric symptoms including depression, suicidal ideation, and behavioral changes 3
- Metoclopramide: Risk of tardive dyskinesia (0.1% per 1000 patient-years) and other extrapyramidal symptoms, particularly in elderly females, diabetics, and those with renal/hepatic impairment 5
The combination may potentiate neuropsychiatric adverse effects through overlapping CNS mechanisms.
Clinical Management Algorithm
If Combination is Unavoidable:
Assess baseline seizure risk factors:
- History of seizures or epilepsy
- Brain metastases or structural brain lesions
- Concurrent medications that lower seizure threshold (antipsychotics, theophylline, systemic corticosteroids)
- Alcohol withdrawal or abrupt benzodiazepine discontinuation
- Eating disorders (bulimia/anorexia)
- Hepatic or renal impairment
If ANY seizure risk factors present: DO NOT combine these medications 3, 4
If no seizure risk factors:
- Use lowest effective dose of bupropion (start 150 mg once daily, maximum 300 mg/day) 3
- Limit metoclopramide to ≤10 mg three times daily for shortest duration possible (ideally <12 weeks) 5
- Monitor closely for:
- New-onset seizures
- Neuropsychiatric symptoms (depression, anxiety, agitation, suicidal thoughts)
- Extrapyramidal symptoms (tremor, rigidity, tardive dyskinesia)
- Gastrointestinal symptoms
High-risk populations requiring dose reduction or avoidance:
Safer Alternatives
Instead of Metoclopramide:
- Ondansetron (5-HT3 antagonist) for nausea/vomiting
- Domperidone (where available; does not cross blood-brain barrier as readily)
- Erythromycin for gastroprokinetic effects
Instead of Bupropion (if for depression):
- Sertraline, escitalopram, or citalopram (minimal CYP2D6 inhibition, no seizure risk amplification)
- Mirtazapine (different mechanism, no CYP2D6 interaction)
Instead of Bupropion (if for smoking cessation):
Critical Pitfalls to Avoid
Do not assume the interaction is benign because metoclopramide is not a CYP2D6 substrate—the concern is pharmacodynamic (additive CNS effects and seizure risk)
Do not use this combination in patients with brain metastases, epilepsy, or eating disorders—this is an absolute contraindication for bupropion 3, 4, 3
Do not prescribe long-term metoclopramide (>12 weeks) even without bupropion due to tardive dyskinesia risk 5
Do not overlook drug-drug-disease interactions: Both medications have multiple contraindications that may overlap in complex patients
The evidence strongly supports avoiding this combination when possible, given the overlapping CNS risks and lack of safety data for concurrent use. When alternatives exist, they should be prioritized to minimize patient harm related to seizures and neuropsychiatric complications.